Literature DB >> 7342289

Vancomycin therapy for infective endocarditis.

J E Geraci, W R Wilson.   

Abstract

The use of vancomycin is increasing for the treatment of serious life-threatening staphylococcal and other bacterial infections, including infective endocarditis, in patients who are allergic to the penicillins. The literature through 1978 reveals approximately 55 cases of infective endocarditis treated with vancomycin alone or with combined antibiotic therapy. Many of these 55 patients were treated by different clinicians, were given variable regimens of therapy, received other therapy before vancomycin, had associated valve replacement; various amounts of data were provided for the reported cases. A summary of these reports indicates a cure in 48 (87%) of the 55 patients. Recent in vitro and in vivo animal and patient data indicate that vancomycin alone or as part of combined therapy is bactericidal and curative in patients allergic to penicillin for infective endocarditis caused by staphylococci and streptococci-both enterococcal and nonenterococcal (Streptococcus bovis and viridans group streptococci) infections. In this study, 10 patients with infective endocarditis were treated with vancomycin or combined therapy; seven were cured. Five of the 10 patients with infective endocarditis caused by viridans streptococci were cured with combined vancomycin-streptomycin given in short-term therapy for two weeks.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7342289

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  13 in total

Review 1.  Resistance of enterococci to glycopeptides.

Authors:  P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Vancomycin-aminoglycoside combinations in therapy of endocarditis caused by Enterococcus species and Streptococcus bovis.

Authors:  J M Besnier; C Leport; A Buré; J L Vildé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

3.  Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.

Authors:  P M Small; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  Application of a Bayesian method to monitor and adjust vancomycin dosage regimens.

Authors:  A K Hurst; M A Yoshinaga; G H Mitani; K A Foo; R W Jelliffe; E C Harrison
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Prophylactic antibiotic administration for post cardiothoracic surgery sternal wounds: a retrospective study.

Authors:  Georgia Pitsiou; Ioannis Kioumis; Konstantinos Zarogoulidis; George Lazaridis; Antonis Papaiwannou; Katerina Tsirgogianni; Anastasia Karavergou; Sofia Lampaki; Aggeliki Rapti; Georgia Trakada; Athanasios Zissimopoulos; Theodoros Karaiskos; Athanasios Madesis; Georgios Drosos; Paul Zarogoulidis
Journal:  Ann Transl Med       Date:  2015-03

6.  Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery.

Authors:  Loren G Miller; James A McKinnell; Michael E Vollmer; Brad Spellberg
Journal:  Infect Control Hosp Epidemiol       Date:  2011-04       Impact factor: 3.254

7.  Cloning and heterospecific expression of the resistance determinant vanA encoding high-level resistance to glycopeptides in Enterococcus faecium BM4147.

Authors:  A Brisson-Noël; S Dutka-Malen; C Molinas; R Leclercq; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 8.  Anti-infective treatment in intensive care: the role of glycopeptides.

Authors:  R N Grüneberg; A P Wilson
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

9.  Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.

Authors:  P Van der Auwera; M Aoun; F Meunier
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

10.  Transferable vancomycin and teicoplanin resistance in Enterococcus faecium.

Authors:  R Leclercq; E Derlot; M Weber; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.